Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia

被引：48
作者：
Ulhaq, Zulvikar Syambani [1 ]
Soraya, Gita Vita [2 ]
机构：
[1] Maulana Malik Ibrahim Islamic State Univ Malang, Dept Biochem, Fac Med & Hlth Sci, Batu 65151, East Java, Indonesia
[2] Hasanuddin Univ, Dept Biochem, Fac Med, Makassar 90245, South Sulawesi, Indonesia
来源：
MEDICINA CLINICA | 2020年 / 155卷 / 12期
关键词：
OFF-LABEL USE; TOCILIZUMAB; INTERLEUKIN-6;
D O I：
10.1016/j.medcli.2020.07.002
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：548 / 556
页数：9
相关论文
共 50 条
  • [41] Cytokine storm and translating IL-6 biology into effective treatments for COVID-19
    Tiantian Li
    Dongsheng Wang
    Haiming Wei
    Xiaoling Xu
    Frontiers of Medicine, 2023, 17 (06) : 1080 - 1095
  • [42] Cytokine storm and translating IL-6 biology into effective treatments for COVID-19
    Tiantian Li
    Dongsheng Wang
    Haiming Wei
    Xiaoling Xu
    Frontiers of Medicine, 2023, 17 : 1080 - 1095
  • [43] Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab
    Araki, Manabu
    Aranami, Toshimasa
    Matsuoka, Takako
    Nakamura, Masakazu
    Miyake, Sachiko
    Yamamura, Takashi
    MODERN RHEUMATOLOGY, 2013, 23 (04) : 827 - 831
  • [44] The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review
    Kaye, Avi Gurion
    Siegel, Robert
    PEERJ, 2020, 8
  • [45] Utility of IL-6 in the Diagnosis, Treatment and Prognosis of COVID-19 Patients: A Longitudinal Study
    Jain, Vikram
    Kumar, Pratap
    Panda, Prasan Kumar
    Suresh, Mohan
    Kaushal, Karanvir
    Mirza, Anissa A.
    Raina, Rohit
    Saha, Sarama
    Omar, Balram J.
    Subbiah, Vivekanandhan
    VACCINES, 2022, 10 (11)
  • [46] Humoral COVID-19 vaccine response in patients with NMOSD/MOGAD during anti-IL-6 receptor therapy compared to other immunotherapies
    Schwake, Carolin
    Pakeerathan, Thivya
    Kleiter, Ingo
    Ringelstein, Marius
    Aktas, Orhan
    Korporal-Kuhnke, Mirjam
    Wildemann, Brigitte
    Jarius, Sven
    Bayas, Antonios
    Pul, Refik
    Ceylan, Ulas
    Faissner, Simon
    Hellwig, Kerstin
    Gomes, Ana Beatriz Ayroza Galvao Ribeiro
    Lipps, Philipp
    Proebstel, Anne-Katrin
    Kuempfel, Tania
    Oswald, Eva
    Bergh, Florian Then
    Goedel, Clemens
    Huemmert, Martin W.
    Trebst, Corinna
    Gold, Ralf
    Ayzenberg, Ilya
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (06) : 757 - 761
  • [47] Computer-aided prediction and design of IL-6 inducing peptides: IL-6 plays a crucial role in COVID-19
    Dhall, Anjali
    Patiyal, Sumeet
    Sharma, Neelam
    Usmani, Salman Sadullah
    Raghava, Gajendra P. S.
    BRIEFINGS IN BIOINFORMATICS, 2021, 22 (02) : 936 - 945
  • [48] Tocilizumab: A novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases
    Alten, Rieke
    Maleitzke, Tazio
    ANNALS OF MEDICINE, 2013, 45 (04) : 357 - 363
  • [49] Interleukin-6 (IL-6) as a Predictor of Clinical Outcomes in Patients with COVID-19
    Mahmood, Saad B. Z.
    Majid, Hafsa
    Arshad, Ainan
    Zaib-Un-Nisa, Noureen
    Niazali, Noureen
    Kazi, Kulsum
    Aslam, Aashir
    Ahmed, Sibtain
    Jamil, Bushra
    Jafri, Lena
    CLINICAL LABORATORY, 2023, 69 (06) : 1126 - 1133
  • [50] Interleukin-6 (IL-6) inhibitors as therapeutic agents for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis
    Pinzon, Rizaldy Taslim
    Wijaya, Vincent Ongko
    Buana, Ranbebasa Bijak
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2021, 14 (08) : 1001 - 1009
12345